Program
safimaltib
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Leukemia, Myeloid, Acute · Lymphoma, Non-Hodgkin, led by Johnson & Johnson.
Furthest: phase 1, since Apr 2, 20194 company-led studies, 1 open or runningNext primary completion: Jan 19, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 41 open or running | phase 1since Apr 2, 2019 | Apr 2, 2019 | Jan 19, 2028phase 1 · NCT06788509 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 2, 2019First study: phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellFirst studyNCT03900598 · 226 enrolled · United States, Australia, China and more
- Dec 1, 2020Phase 1 study in Lymphoma, Non-HodgkinNCT04657224 · 75 enrolled · United States, Australia, Belgium and more
- May 4, 2021Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellNCT04876092 · 45 enrolled · Denmark, France, Poland and more
- Jan 16, 2025Phase 1 study in Leukemia, Myeloid, AcuteNCT06788509 · 120 planned · Australia, Belgium, Denmark and more
Ahead
- Jan 19, 2028Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT06788509
TargetBeta
MALT1 →read by rule
“An orally bioavailable inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), ”NCIt, by rule
Other programs on MALT1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| CARD11-BCL10-MALT1 Complex Inhibitor XL114rule | Dr. Reddy's Laboratories | phase 1 | 2 |
| ZE66-0205rule | eilean-therapeutics | phase 1 | 1 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06788509Leukemia, Myeloid, Acute · Australia, Belgium, Denmark and more | 1 | By invitation | Jan 19, 2028 | 120 |
| NCT04876092Leukemia, Lymphocytic, Chronic, B-Cell · Denmark, France, Poland and more | 1 | Completed | Feb 13, 2025 | 45 |
| NCT04657224Lymphoma, Non-Hodgkin · United States, Australia, Belgium and more | 1 | Completed | Jan 16, 2025 | 75 |
| NCT03900598Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, China and more | 1 | Completed | May 22, 2025 | 226 |
How it is read
Names in the registry
- “JNJ-67856633”, 4 entries
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 2 studies
- Leukemia, Myeloid, Acute, 1 study
- Lymphoma, Non-Hodgkin, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.